Compass Therapeutics (NASDAQ:CMPX) Hits New 52-Week High – Still a Buy?

Compass Therapeutics, Inc. (NASDAQ:CMPX) reached a new 52-week high on Wednesday . The company traded as high as $6.17 and last traded at $6.0150, with a volume of 5307031 shares trading hands. The stock had previously closed at $5.58.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CMPX. Citigroup started coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They set an “outperform” rating on the stock. Leerink Partnrs raised shares of Compass Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 26th. Citizens Jmp initiated coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 price objective for the company. William Blair assumed coverage on shares of Compass Therapeutics in a report on Monday, January 5th. They set an “outperform” rating on the stock. Finally, Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Compass Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $12.23.

Compass Therapeutics Stock Down 1.7%

The stock has a market cap of $1.01 billion, a PE ratio of -12.67 and a beta of 1.45. The business’s 50-day simple moving average is $5.19 and its 200-day simple moving average is $4.02.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. As a group, equities research analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently modified their holdings of the stock. Strs Ohio purchased a new stake in Compass Therapeutics in the first quarter worth about $34,000. Simplicity Wealth LLC grew its holdings in shares of Compass Therapeutics by 81.8% during the 2nd quarter. Simplicity Wealth LLC now owns 84,636 shares of the company’s stock worth $220,000 after acquiring an additional 38,093 shares during the period. Creative Planning bought a new position in shares of Compass Therapeutics in the 2nd quarter worth approximately $30,000. XTX Topco Ltd purchased a new position in shares of Compass Therapeutics in the 2nd quarter valued at approximately $84,000. Finally, Invesco Ltd. lifted its stake in shares of Compass Therapeutics by 58.1% in the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after purchasing an additional 21,578 shares during the period. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.